Is Cellectis Stock a Good Investment?

Cellectis Investment Advice

CLLS

To provide specific investment advice or recommendations on Cellectis SA stock, we recommend investors consider the following general factors when evaluating Cellectis SA. This will help you to make an informed decision on whether to include Cellectis in one of your diversified portfolios:

Examine Cellectis' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
Research Cellectis' leadership team and their track record. Good management can help Cellectis navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
Consider the overall health of the Biotechnology space and any emerging trends that could impact Cellectis' business and its evolving consumer preferences.
Compare Cellectis' performance and market position to its competitors. Analyze how Cellectis is positioned in terms of product offerings, innovation, and market share.
Check if Cellectis pays a dividend and its dividend yield and payout ratio.
Review what financial analysts are saying about Cellectis' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.

It's important to note that investing in Cellectis SA stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Cellectis SA is a good investment.

Sell

Buy

Strong Sell

We provide trade advice to complement the prevailing expert consensus on Cellectis SA. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure Cellectis is not overpriced, please confirm all Cellectis SA fundamentals, including its price to book, current ratio, working capital, as well as the relationship between the net income and target price . Please also double-check Cellectis SA price to earning to validate your buy or sell decision is consistent with all fundamental data available and that the company can sustain itself in the current economic cycle.

Market Performance	Weak	Details
Volatility	Relatively risky	Details
Hype Condition	Under hyped	Details
Current Valuation	Undervalued	Details
Odds Of Distress	Average	Details
Economic Sensitivity	Hyperactively responds to market trends	Details
Investor Sentiment	Impartial	Details
Analyst Consensus	Strong Buy	Details
Financial Strenth (F Score)	Poor	Details
Financial Leverage	Inapplicable	Details
Reporting Quality (M-Score)	Possible Manipulator	Details

Examine Cellectis Stock

Researching Cellectis' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 15.0% of the company shares are held by institutions such as insurance companies. The book value of Cellectis was currently reported as 1.3. The company recorded a loss per share of 1.92. Cellectis SA had not issued any dividends in recent years.

To determine if Cellectis is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cellectis' research are outlined below:

	Cellectis SA had very high historical volatility over the last 90 days
	Cellectis SA has high likelihood to experience some financial distress in the next 2 years
	The company reported the previous year's revenue of 755 K. Net Loss for the year was (109.45 M) with profit before overhead, payroll, taxes, and interest of 23.95 M.
	Cellectis SA currently holds about 153.13 M in cash with (25.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.37, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
	Cellectis SA has a poor financial position based on the latest SEC disclosures
	Latest headline from seekingalpha.com: Cellectis announces CFO departure

Cellectis Quarterly Accounts Payable

19.07 Million

Cellectis uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cellectis SA. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cellectis' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.

	13th of March 2024 Upcoming Quarterly Report	View
	2nd of May 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	13th of March 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

Earnings surprises can significantly impact Cellectis' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Cellectis' investors have experienced.

Reported	Fiscal Date	Estimated EPS	Reported EPS	Surprise
2018-11-13	2018-09-30	-0.61	-0.54	0.07	11
2020-11-05	2020-09-30	-0.61	-0.69	-0.08	13
2023-05-04	2023-03-31	-0.48	-0.58	-0.1	20
2015-11-19	2015-09-30	-0.3	-0.4	-0.1	33
2023-11-06	2023-09-30	-0.42	-0.31	0.11	26
2020-03-05	2019-12-31	-0.77	-0.88	-0.11	14
2023-03-08	2022-12-31	-0.71	-0.59	0.12	16
2022-08-04	2022-06-30	-0.56	-0.42	0.14	25

Know Cellectis' Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Cellectis is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cellectis SA backward and forwards among themselves. Cellectis' institutional investor refers to the entity that pools money to purchase Cellectis' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.

		Shares
D. E. Shaw & Co Lp	2023-09-30	47.2 K
Citadel Advisors Llc	2023-09-30	34.3 K
Susquehanna International Group, Llp	2023-12-31	19.5 K
Bnp Paribas Arbitrage, Sa	2023-12-31	15.8 K
Wells Fargo & Co	2023-12-31	14.3 K
Geode Capital Management, Llc	2023-12-31	10.8 K
Advisor Group Holdings, Inc.	2023-12-31	4.6 K
Qube Research & Technologies	2023-12-31	4.5 K
Rhumbline Advisers	2023-12-31	3.9 K
Long Focus Capital Management, Llc	2023-12-31	4.5 M
Capital Research & Mgmt Co - Division 3	2023-12-31	1.8 M

Note, although Cellectis' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Cellectis' market capitalization trends

The company currently falls under 'Small-Cap' category with a current market capitalization of 215.54 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cellectis's market, we take the total number of its shares issued and multiply it by Cellectis's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Market Cap

166.82 Million

Cellectis' profitablity analysis

Cellectis' profitability indicators refer to fundamental financial ratios that showcase Cellectis' ability to generate income relative to its revenue or operating costs. If, let's say, Cellectis is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Cellectis' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Cellectis' profitability requires more research than a typical breakdown of Cellectis' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.

	Last Reported	Projected for Next Year
Return On Tangible Assets	(0.30)	(0.32)
Return On Capital Employed	(0.60)	(0.63)
Return On Assets	(0.30)	(0.32)
Return On Equity	(1.19)	(1.25)

Determining Cellectis' profitability involves analyzing its financial statements and using various financial metrics to determine if Cellectis is a good buy. For example, gross profit margin measures Cellectis' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cellectis' profitability and make more informed investment decisions.

The data published in Cellectis' official financial statements usually reflect Cellectis' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Cellectis SA. For example, before you start analyzing numbers published by Cellectis accountants, it's critical to develop an understanding of what Cellectis' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.

Please note, the presentation of Cellectis' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cellectis' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Cellectis' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cellectis SA. Please utilize our Beneish M Score to check the likelihood of Cellectis' management manipulating its earnings.

Evaluate Cellectis' management efficiency

Cellectis SA has return on total asset (ROA) of (0.2043) % which means that it has lost $0.2043 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1094) %, meaning that it created substantial loss on money invested by shareholders. Cellectis' management efficiency ratios could be used to measure how well Cellectis manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.32 in 2024. Return On Capital Employed is likely to drop to -0.63 in 2024. At this time, Cellectis' Other Current Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 243.1 M in 2024, whereas Total Assets are likely to drop slightly above 270.8 M in 2024.

	Last Reported	Projected for Next Year
Book Value Per Share	1.49	1.41
Net Current Asset Value	0.00	0.00
Tangible Asset Value	0.00	0.00
Tangible Book Value Per Share	1.47	1.40
Enterprise Value Over EBITDA	(1.50)	(1.42)
Price Book Value Ratio	2.07	1.97
Enterprise Value Multiple	(1.50)	(1.42)
Price Fair Value	2.07	1.97
Enterprise Value	131.7 M	125.2 M

The analysis of Cellectis' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Cellectis' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Cellectis Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.

Beta

3.134

Basic technical analysis of Cellectis Stock

As of the 4th of May, Cellectis shows the Downside Deviation of 3.32, mean deviation of 2.6, and Risk Adjusted Performance of 0.0233. Cellectis SA technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate nineteen technical drivers for Cellectis SA, which can be compared to its peers. Please confirm Cellectis SA downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Cellectis SA is priced correctly, providing market reflects its regular price of 2.99 per share. Please also double-check Cellectis SA total risk alpha, which is currently at (0.19) to validate the company can sustain itself at a future point.

Understand Cellectis' technical and predictive indicators

Using predictive indicators to make investment decisions involves analyzing Cellectis' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.

	Risk Adjusted Performance	0.0233
	Market Risk Adjusted Performance	0.0428
	Mean Deviation	2.6
	Semi Deviation	3.11
	Downside Deviation	3.32
	Coefficient Of Variation	4285.04
	Standard Deviation	3.75
	Variance	14.03
	Information Ratio	0.0086
	Jensen Alpha	(0.03)
	Total Risk Alpha	(0.19)
	Sortino Ratio	0.0097
	Treynor Ratio	0.0328
	Maximum Drawdown	12.42
	Value At Risk	(5.54)
	Potential Upside	4.76
	Downside Variance	11.04
	Semi Variance	9.68
	Expected Short fall	(2.95)
	Skewness	1.43
	Kurtosis	6.6

	Risk Adjusted Performance	0.0233
	Market Risk Adjusted Performance	0.0428
	Mean Deviation	2.6
	Semi Deviation	3.11
	Downside Deviation	3.32
	Coefficient Of Variation	4285.04
	Standard Deviation	3.75
	Variance	14.03
	Information Ratio	0.0086
	Jensen Alpha	(0.03)
	Total Risk Alpha	(0.19)
	Sortino Ratio	0.0097
	Treynor Ratio	0.0328
	Maximum Drawdown	12.42
	Value At Risk	(5.54)
	Potential Upside	4.76
	Downside Variance	11.04
	Semi Variance	9.68
	Expected Short fall	(2.95)
	Skewness	1.43
	Kurtosis	6.6

Consider Cellectis' intraday indicators

Cellectis intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cellectis stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

	Accumulation Distribution	0.12
	Daily Balance Of Power	1.216216
	Rate Of Daily Change	1.18
	Day Median Price	2.83
	Day Typical Price	2.88
	Market Facilitation Index	0.37
	Price Action Indicator	0.39
	Period Momentum Indicator	0.45

Cellectis Corporate Filings

6K	3rd of May 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.	View Verify
	29th of April 2024 Other Reports	View Verify
13A	14th of February 2024 An amended filing to the original Schedule 13G	View Verify
F3	16th of November 2023 An amendment to the original Schedule 13D filing	View Verify

Cellectis time-series forecasting models is one of many Cellectis' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cellectis' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Cellectis Stock media impact

Far too much social signal, news, headlines, and media speculation about Cellectis that are available to investors today. That information is available publicly through Cellectis media outlets and privately through word of mouth or via Cellectis internal channels. However, regardless of the origin, that massive amount of Cellectis data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.

A primary focus of Cellectis news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Cellectis relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Cellectis' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Cellectis alpha.

Cellectis Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Cellectis can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.

Cellectis announces the drawdown of the ...

recently @ finance.yahoo.com

Bullish

Monthly information on share capital and...

recently @ finance.yahoo.com

Bullish

Cellectis Reports Results from Sharehold...

recently @ finance.yahoo.com

Neutral

Monthly information on share capital and...

recently @ finance.yahoo.com

Bullish

L’Assemblée Générale Extraordinaire de C...

recently @ www.globenewswire.com

Neutral

Cellectis Announces the execution of the...

recently @ www.globenewswire.com

Neutral

Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Cellectis without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Bollinger Bands Now

Bollinger Bands

Use Bollinger Bands indicator to analyze target price for a given investing horizon

All Next

Launch Module

Cellectis Corporate Directors

Cellectis corporate directors refer to members of a Cellectis board of directors. The board of directors generally takes responsibility for the Cellectis' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Cellectis' board members must vote for the resolution. The Cellectis board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.

Laurent Arthaud	Director	Profile
Pierre Bastid	Director	Profile
Alain Godard	Advisor, Independent Director and Member of Compensation Committee	Profile
Herve Hoppenot	Non-Executive Independent Director	Profile

How to buy Cellectis Stock?

Examine Cellectis' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
Research Cellectis' leadership team and their track record. Good management can help Cellectis navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
Consider the overall health of the Biotechnology space and any emerging trends that could impact Cellectis' business and its evolving consumer preferences.
Compare Cellectis' performance and market position to its competitors. Analyze how Cellectis is positioned in terms of product offerings, innovation, and market share.
Check if Cellectis pays a dividend and its dividend yield and payout ratio.
Review what financial analysts are saying about Cellectis' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.

Already Invested in Cellectis SA?

The danger of trading Cellectis SA is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Cellectis is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Cellectis. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Cellectis SA is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.

When determining whether Cellectis SA is a strong investment it is important to analyze Cellectis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cellectis' future performance. For an informed investment choice regarding Cellectis Stock, refer to the following important reports: